One of the tiniest organisms on Earth. One of the largest opportunities in Nutrition.
Live - Open for investment SeaO2 Nutrition (SeaO2 Algae P/L)
SeaO2 Nutrition (SeaO2 Algae Pty Ltd) | Equity Crowdfunding
Min reached. Now targeting $500,000
$262,860
Raised84
InvestorsOn-Market BookBuilds Pty Ltd (ABN 31 140 632 024) (“OnMarket”) operates under an Australian Financial Services Licence (AFSL 421 535) issued by the Australian Securities and Investments Commission.
Please consider the offer document and general risk warning before investing.
Retail investors are entitled to a 5 day cooling-off period.
Investments over $10,000 are restricted to Sophisticated investors - Apply here
Click here to learn more about Equity Crowdfunding
Microalgae fuelled evolution. We're unleashing its potential now.
SeaO2's purpose is to take microalgae from untapped potential to a global nutrition solution. We grow Nannovia™, a marine microalgae naturally rich in omega-3. It's the source fish get their Omega-3 from. However, Nannovia™ arrives as a consumer-ready powder, not an oil: sustainable, scalable, and ready to drop into everyday foods and supplements.
Omega-3 is one of the most important nutrients for cellular health: heart, brain, mood, eyes, immunity. Yet over 80% of people in the developed world don't get enough of it, and the ocean we've relied on to supply it is running short.
We think there's a better way, and it's been at the beginning of the food chain the whole time.
We've already built the facility, earned the certifications, and started selling.
This raise is about scaling the vision: new product formats, new offerings like astaxanthin, and more capacity, so this solution can reach people everywhere.
Want to know more? Watch the Investor Q&A here.
$7M facility built, certified, and already generating revenue
- Australia's largest food grade microalgae facility; designed, built and operated in-house.
- GMP & HACCP certified, with independent safety and digestibility analysis from the University of Queensland.
- $3M in matched funding from the Australian Government's CRC-P grant program (~$1M received to date, and $2M still to come).
- Over $500,000 of product sold (retail value) in our first season, plus $150,000+ in contract cultivation revenue.
World leading technology, proprietary (exclusive & royalty-free) strains
- SeaO2 Nutrition have built a uniquely capable facility – perhaps the world’s most advanced for production of phototrophic microalgae (grows using just light and photosynthesis to make it’s own food).
- The facility is capable of growing difficult to produce microalgae species, as well as easier ones, with highly consistent nutritional properties and food grade quality.
- Our first proprietary product is a Nannochloropsis microalgae distinctively high in Omega-3 EPA; Nannovia™.
- To date, Nannovia™ has been sold wholesale to a small number of supplement brands. All have re-ordered. Retail value of these sales is approx. $500k.
- A further 20+ health brands are currently in discussion.
- We have capacity to produce 75,000kg of Nannovia™ p.a.
- SeaO2 Nutrition will begin retailing Nannovia™ in late 2026, with various blends planned for 2027.
- Additional microalgae species are planned for commercial launch in 2027.
- SeaO2 Nutrition also offer contract cultivation services, and have been the primary supplier for PhycoHealth since late 2025.
SeaO2 has solved the supplement industry's Omega-3 EPA supply issue
- Nannovia™ sits within a small, under-served niche inside a growing category - not a broad, contested market.
- The total microalgae industry is valued at roughly US$15B (2026).
- Algae-derived omega-3 represents only 7–9% of that industry (~US$1.0–1.3B), and within that segment, DHA-dominant products (Schizochytrium, Crypthecodinium) command 2/3 of share.
- Nannovia's EPA-dominant profile addresses the remaining, structurally under-served 1/3 - a genuine white-space, rather than a crowded-market.
- Dwindling fish stocks and increasing demand means the annual global gap of EPA and DHA supply has already reached 1.1 million tons (Schade et al. 2020).
- Supplement companies need it, they want it, and at SeaO2 we've made it- in a way that's better for the planet, and healthier for people.
Delivering innovative technology is tough. Milestones matter.
- Facility designed, approved - Construction starts (Feb 2023)
- Construction Completed (Jul 2024)
- Commissioning Completed (Dec 2024)
- 1st wholesale Nannovia™ sale (May 2025)
- Food and Beverage Accelerator grant Awarded (June 2025)
- CRC-P Grant Awarded (Aug 2025)
- 1st Contract Cultivation Sale (Sep 2025)
- GMP & HACCP Accreditation Awarded (Dec 2025)
- Haematococcus successfully harvested from green-house pond
- (Mar 2026)
- $3,818,253 additional equity contributed by Co-Founder Peter Philipp (Oct 2026)
- - - - - - - - - - - - - - - - - - - - - - - - - - - -
- 1st retail Nannovia sale (Nov 2026)
- Crowd Sourced Funding secured (Nov 2026)
- US Regulatory approval – Self-Affirmed GRAS (Mar 2027)
- 1st Haematococcus sale (Mar 2027)
- 1st significant Nannovia sale to US (Oct 2027)
This technology is difficult to replicate
Nannovia™ is a powder, not an oil. Shelf stable, whole cell, and unlike fish oil it drops straight into health foods and supplements. That creates opportunities the incumbents and their oils can't reach.
One facility, multiple products. The plant was designed to run a broad range of algal species across salt and fresh water. We're already producing a proprietary seaweed strain under contract for PhycoHealth, with two more species in scale-up
Shareholder support is appreciated
Shareholders investing will receive all the benefits listed up to their investment amount.
- $350: 50% discount on 1st order of Nannovia™ (10% discount ongoing)
- $1,000: Nannovia™ Tote Bag
- $3,000: Nannovia™ Drink Bottle
- $5,000: Site Tour
- $10,000: 12 month supply of Nannovia™
- $20,000: Dinner or Lunch with Dr Skye Thomas-Hall
The Team
Peter Philip
Co-Founder / Advisor
Gian Minns
Co-Founder / Director
Dr Skye Thomas-Hall
Co-Founder / CEO
Stephen Conti
Production Manager
Jean-Baptiste Rouxel
Cultivation Manager
Marsanne Chabert
Quality Control Manager
Dr Reuben Brown
Process Engineer
Terms of the Offer
Issued Capital
Before the Offer
Following the Offer
For more detailed information, please read the Capital Structure section of the offer document.
Use of Funds
For more detailed information, please read the Use of Funds section of the offer document.
Company Risks
Almost all the world's omega-3 comes from fish, but the ocean can't keep up; fish supply is tightening, and demand keeps climbing. SeaO2 have built the alternative - the source the fish get it from: microalgae. As with any growth business, an investment in the Company should be seen as high-risk and speculative. A description of the main risks that may impact their business are listed in the offer document. Investors should read this section carefully before deciding to apply for shares under the Offer. There are also other, more general, risks associated with the Company (for example, customer adoption and commercialisation, working capital and further funding, production reliability, capacity and margins, food safety, product quality and shelf life, regulatory requirements and market access, dependence on one production site, reliance on commerial and processing partners, grant commitments and R&D tax benefits, or the inability to sell their shares). See the Risk section in the Offer Document for further information.
The Offer is subject to a Maximum Subscription amount of $1,530,000. If the Maximum Subscription is reached, the Offer will close early. Applications will be treated on a time priority basis and may be subject to scale back, so please fund your application as soon as possible.
RISK WARNING: Crowd-sourced funding is risky. Issuers using this facility include new or rapidly growing ventures. Investment in these types of ventures is speculative and carries high risks. You may lose your entire investment, and you should be in a position to bear this risk without undue hardship. Even if the company is successful, the value of your investment and any return on the investment could be reduced if the company issues more shares. Your investment is unlikely to be liquid. This means you are unlikely to be able to sell your shares quickly or at all if you need the money or decide that this investment is not right for you.
Even though you have remedies for misleading statements in the replacement offer document or misconduct by the company, you may have difficulty recovering your money. There are rules for handling your money. However, if your money is handled inappropriately or the person operating this platform becomes insolvent, you may have difficulty recovering your money. Ask questions, read all information given carefully, and seek independent financial advice before committing yourself to any investment.
5 DAY COOLING OFF PERIOD: There is a 5 business day cooling off period for retail investors. During this period, you may withdraw your application and receive a full refund into your nominated refund account. Please note: After the 5 day cooling off period has expired, you will be unable to withdraw your application. More information here.
ONMARKET FEES: Upon successful completion of the Offer, a maximum fee of 6.5% of the funds raised will be paid to OnMarket by the Company.
ONMARKET INTERESTS: OnMarket and its associates may be participating in this offer.
ONMARKET INTERESTS AND AMOUNTS SUBJECT TO COOLING OFF: The funding bar displayed under each crowd funding offer may include applications where payments are yet to be made and amounts that are subject to the cooling off period.
Section 734(6) disclosure: The issuer of the securities is Sea02 Algae Pty Ltd, ACN: 666427121. The securities to be issued are fully-paid ordinary shares. The disclosure document for the offer can be obtained by clicking on the link above. The offers of the securities are made in, or accompanied by, a copy of the disclosure document. Investors should consider the disclosure document in deciding whether to acquire the securities. Anyone who wants to acquire the securities will need to complete the application form that will be in or will accompany the disclosure document (which can be done via the electronic application form which will become available by clicking the bid button above)
Question time
We'd love to answer your questions, we'll have one of the OnMarket team or the company representative of the offer get back to you asap. So ask away ...
At your current wholesale price, which existing ingredient or ingredient blend can a customer replace with Nannovia and reduce their total formulation below existing feedstock cost?. If not, what wholesale price is necessary yo be commercially competitive in the wholesale market?
Tim M (OnMarket member) on 03/11/2026Great question. As a swap out for Omega-3 "oil" Nannovia is more expensive than fish sources.
Gian M (SeaO2 Nutrition (SeaO2 Algae P/L) representative) replied to Tim M on 10/11/2026But that's not what Nannovia is.
Nannovia's value is greater in 3 ways;
1 - Broader nutritional value. Nannovia is more than "just" Omega-3. Nannovia also contains beneficial quantities of Folate, B12, lutein, zeaxanthin, iron, Omega-7 and more. If you add up the cost of all those components, it's compelling.
2 Shelf stable powder. Its difficult to fortify everyday foods (breads, cereals, health bars) with Omega-3s from fish oil or algal oil both oxidisation and flavour are problematic. Importantly, Nannovia is not an oil its a shelf stable powder. This creates an almost uncontested market for Omega-3 fortification of everyday foods.
3- So many more. Additional differentiating features include being vegan, Australian providence, sustainability, and quality accreditations. Also, security of supply whilst Peruvian anchovy harvests get cancelled (50% of global supply) Nannovia continues to grow with zero impact or dependency on our oceans.
Thanks for the question.
Regards,
Gian
Hi, Have you, or do you intend to provide in the future, verifiable, controlled blind studies to confirm/deny the efficacy of your product e.g. Nannovia?
Jay L (OnMarket member) on 09/11/2026The supplement market is inundated with, often eroneous , claims of benefits that various products claiming to be beneficial to one's health with constant supplementation. For a consumer, the marketplace is an absolute mindfield of misinformation or indeed blatant untruths.
The way around this ,from a consumers' perspective, is being able to read verifiable trials and Trustpilot verified reviews rather than so-called reviews from customers on your own website.
There are a plethora of dodgy claims in the marketplace. You only have to google Nattokinase to be bamboozled with claims, and anti claims, of each others' products.
How do you intend to circumvent this marketplace conundrum with your products to prove their efficacy and health benefits, and separate yourselves from the "Dodgy Brothers"?
Jay.....intending investor
Hi Jay,
Skye T (OnMarket member) replied to Jay L on 10/11/2026Thank you for raising thisyoure right to ask for evidence that can be independently checked.
We have completed an **in-vitro study with the University of Queensland**, summarised on our [science page](https://www.seao2nutrition.com/science#research). This supports our processing approach and demonstrates the release and accessibility of nutrients during simulated digestion. It does **not**, by itself, establish health benefits in humans.
**We have not yet conducted human clinical trials on Nannovia, but we intend to.** Well-designed, randomised, blinded, controlled trials are the next step in testing product-specific efficacy.
There is already relevant human research:
- The [NovAL study](https://www.mdpi.com/2072-6643/15/7/1645), using whole biomass from a closely related species, reported increased blood EPA levels, alongside other findings that warrant further investigation.
- A [Brisbane randomised, double-blind, placebo-controlled trial](https://www.mdpi.com/2072-6643/12/6/1869) of a Nannochloropsis extract reported improvements in omega-3 status and selected cholesterol measures.
These are encouraging. For broader context, here are my [recent co-authored review on EPA and Nannochloropsis oceanica](https://www.mdpi.com/1422-0067/27/21/9834) and an [overview of Nannochloropsis nutrition research](https://www.sciencedirect.com/science/article/pii/S1756464620301432).
Our approach is to make the evidence accessible and be clear about what it doesand does notdemonstrate. Customer reviews can describe experiences, but cannot replace controlled trials.
Youd also be very welcome to visit our farm and see our cultivation, processing and quality systems firsthand.
Best regards,
Skye
Another key point: A year ago we recieved HACCP and GMP certification, validating the compliance and safety of our process.
Skye T (SeaO2 Nutrition (SeaO2 Algae P/L) representative) replied to Skye T on 10/11/2026Thank you Skye....looks like I have some reading to do.
Jay L (OnMarket member) replied to Skye T on 11/11/2026As an investor, I like to find that the company I am interested in, has an advantage over it's competitors , which is why I asked, so any news of said advantages in turn, encourages investors and hopefully profit along the way.
Thank you for your comprehensive response and kind invitation to your facility. I am also a shareholder in Phyco and have to get down to visit Pia in the near future.
Best of luck with your Raise.
Jay
Please sign in to post a question